FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

Volker Heinemann, Sebastian Stintzing, Michael Scholz et al.|The Lancet Oncology|2014

Cited by 1.7k